Search Within

Matthew David Hellmann

  1. "2021"
Formats
  1. Meeting Abstract (21)
  2. Journal Article (18)
  3. Correspondence (1)
Groups
  1. Department of Medicine (40)
  2. Solid Tumor Oncology Division (40)
  3. Thoracic Oncology (40)
  4. Weinberg Fellows (14)
  5. Radiology, Department of (10)
  6. Body Imaging Service (9)

More Groups

People
  1. Hira Rizvi (14)
  2. Andrew Plodkowski (9)
  3. Kathryn Arbour (7)
  4. Jia Luo (6)
  5. Mark Kris (6)
  6. Jacklynn Egger (5)

More People

Years
  1. 2021 (40)
Publications
  1. Annals of Oncology (8)
  2. Journal of Clinical Oncology (6)
  3. Journal for ImmunoTherapy of Cancer (5)
  4. Journal of Thoracic Oncology (5)
  5. Clinical Cancer Research (4)
  6. Cancer Research (3)

More Publications

Publishers
  1. American Association for Cancer Research (8)
  2. Oxford University Press (8)
  3. American Society of Clinical Oncology (6)
  4. Elsevier Inc. (6)
  5. Biomed Central Ltd (5)
  6. Cell Press (3)

More Publishers

Results (40)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase 3 study of first-line pembrolizumab with and without vibostolimab (anti-TIGIT) in patients with PD-L1-positive metastatic NSCLC
    Meeting Abstract

    Hellmann, M.; Cho, B.; Juergens, R.; Cheng, Y.; de Castro, G.; Erman, M.; Bauman, J.; Takahashi, T.; Schwarzenberger, P.; Zhang, P.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Keynote-495/keyimpact: Interim analysis of a randomized, biomarker-directed, phase 2 trial of pembrolizumab-based combination therapy for non-small cell lung cancer (Nsclc)
    Meeting Abstract

    Gutierrez, M.; Lam, W. S.; Hellmann, M.; Gubens, M.; Aggarwal, C.; Tan, D. S. W.; Felip, E.; Chiu, J. W. Y.; Lee, J. S.; Yang, J. C. H.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Development and validation of a neoantigen-specific T cell gene signature to identify antitumor T cells in lung cancer and melanoma
    Meeting Abstract

    Zhang, J.; Caushi, J.; Oliveira, G.; Zhang, B.; Ji, Z.; Naidoo, J.; Marrone, K.; Taube, J.; Hellmann, M.; Brahmer, J.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Associations between KIR/KIR-ligand genotypes and clinical outcome for patients with advanced solid tumors receiving BEMPEG plus nivolumab combination therapy in the PIVOT-02 trial
    Meeting Abstract

    Feils, A.; Erbe, A.; Birstler, J.; Kim, K.; Hoch, U.; Currie, S.; Nguyen, T.; Yu, D.; Siefker-Radtke, A.; Tannir, N.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): 4-year update from CheckMate 227
    Meeting Abstract

    Schumann, C.; Paz-Ares, L.; Ciuleanu, T. E.; Lee, J. S.; Urban, L.; Caro, R. B.; Park, K.; Sakai, H.; Ohe, Y.; Nishio, M.; more...
    Oncology Research and Treatment (2021)

    Fulltext@MSK | Save
  • Nivolumab (NIVO) + ipilimumab (IPI) as first-line (1L) treatment (tx) for patients (pts) with advanced NSCLC (aNSCLC) and baseline (BL) brain metastases (mets): Intracranial and systemic outcomes from CheckMate 227 Part 1
    Meeting Abstract

    Reck, M.; Ciuleanu, T. E.; Pluzanski, A.; Lee, J. S.; Bernabe Caro, R.; Linardou, H.; Burgers, J.; Gallardo, C.; Nishio, M.; Peters, S.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Nivolumab (NIVO) + ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced NSCLC (aNSCLC) in CheckMate 227 part 1: Efficacy by KRAS, STK11, and KEAP1 mutation status
    Meeting Abstract

    Ramalingam, S. S.; Balli, D.; Ciuleanu, T. E.; Pluzanski, A.; Lee, J. S.; Schenker, M.; Caro, R. B.; Lee, K. H.; Bartolucci, R.; Audigier-Valette, C.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Phase 3 study of first-line pembrolizumab ± vibostolimab (anti-TIGIT) in patients with PD-L1‒positive metastatic NSCLC
    Meeting Abstract

    Hellmann, M. D.; Cho, B. C.; Juergens, R.; Cheng, Y.; De Castro, G. Jr; Erman, M.; Bauman, J. R.; Takahashi, T.; Schwarzenberger, P.; Zhang, P.; more...
    Journal of Thoracic Oncology (2021)

    Fulltext@MSK | Save
  • Nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): 4-year update from CheckMate 227
    Meeting Abstract

    Paz-Ares, L. G.; Ciuleanu, T. E.; Lee, J. S.; Urban, L.; Caro, R. B.; Park, K.; Sakai, H.; Ohe, Y.; Nishio, M.; Pluzanski, A.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Association of a very high tumor mutational load with increased CD8+ and PD-1+ T-cell infiltration and improved clinical outcomes to PD-(L)1 blockade across different PD-L1 expression levels in non-small cell lung cancer
    Meeting Abstract

    Ricciuti, B.; Arbour, K. C.; Alessi, J. V. M.; Mahadevan, N.; Lindsay, J.; Sinha, R.; Vokes, N. I.; Recondo, G.; Lamberti, G.; Rizvi, H.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save